View : 24 Download: 0
Effect of conjugated linoleic acid, μ-calpain inhibitor, on pathogenesis of Alzheimer's disease
- Effect of conjugated linoleic acid, μ-calpain inhibitor, on pathogenesis of Alzheimer's disease
- Lee E.; Eom J.-E.; Kim H.-L.; Baek K.H.; Jun K.-Y.; Kim H.-J.; Lee M.; Mook-Jung I.; Kwon Y.
- Ewha Authors
- 이민영; 김화정; 권영주
- SCOPUS Author ID
- 이민영; 김화정; 권영주
- Issue Date
- Journal Title
- Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
- vol. 1831, no. 4, pp. 709 - 718
- SCI; SCIE; SCOPUS
- μ-Calpain is a calcium-dependent cysteine protease, which is activated by μM concentration of calcium in vitro. Disrupted intracellular calcium homeostasis leads to hyper-activation of μ-calpain. Hyper-activated μ-calpain enhances the accumulation of β-amyloid peptide by increasing the expression level of β-secretase (BACE1) and induces hyper-phosphorylation of tau along with the formation of neurofibrillary tangle by mediating p35 cleavage into p25, both of which are the major mechanisms of neurodegeneration in Alzheimer's disease (AD). Hence, inhibition of μ-calpain activity is very important in the treatment and prevention of AD. In this study, conjugated linoleic acid (CLA), an eighteen-carbon unsaturated fatty acid, was discovered as a μ-calpain-specific inhibitor. CLA showed neuroprotective effects against neurotoxins such as H2O2 and Aβ1-42 in SH-SY5Y cells, and inhibited Aβ oligomerization/fibrillation and Aβ-induced Zona Occludens-1 degradation. In addition, CLA decreased the levels of proapoptotic proteins, p35 conversion to p25 and tau phosphorylation. These findings implicate CLA as a new core structure for selective μ-calpain inhibitors with neuroprotective effects. CLA should be further evaluated for its potential use as an AD therapeutic agent. © 2012 Elsevier B.V.
- Appears in Collections:
- 자연과학대학 > 화학·나노과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.